Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.410
-0.120 (-2.65%)
At close: Dec 20, 2024, 4:00 PM
4.130
-0.280 (-6.35%)
After-hours: Dec 20, 2024, 4:33 PM EST
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
2.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Venus Concept | 67.20M |
| NanoVibronix | 3.29M |
| Akanda | 2.51M |
| Biodexa Pharmaceuticals | 104.90K |
| Cyclacel Pharmaceuticals | 74.00K |
APVO News
- 9 days ago - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Accesswire
- 9 days ago - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Accesswire
- 17 days ago - Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - Accesswire
- 22 days ago - Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - Accesswire
- 25 days ago - Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - Accesswire
- 4 weeks ago - Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - Accesswire
- 4 weeks ago - First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Accesswire
- 5 weeks ago - First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - Accesswire